Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C L Bevan

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Oncogene|December 20, 2011
Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgensD A Dart, G N Brooke, A Sita-Lumsden, et al.
Archives of Disease in Childhood|June 1, 1997
Phenotypic diversity in siblings with partial androgen insensitivity syndromeB A Evans, I A Hughes, C L Bevan, et al.
Human Molecular Genetics|February 1, 1996
Functional analysis of six androgen receptor mutations identified in patients with partial androgen insensitivity syndromeC L Bevan, B B Brown, H R Davies, et al.
Biochemical Society Transactions|November 1, 2006
Mechanisms of androgen receptor repression in prostate cancerS M Powell, G N Brooke, H C Whitaker, et al.
Nature Communications|July 2, 2021
The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cellsD A Leach, A Mohr, E S Giotis, et al.
Oncogene|September 12, 2006
Prohibitin, a protein downregulated by androgens, represses androgen receptor activityS C Gamble, D Chotai, M Odontiadis, et al.
International Journal of Obesity (2005)|July 18, 2020
High fat diet causes distinct aberrations in the testicular proteomeS Jarvis, L A Gethings, L Samanta, et al.
Endocrine Oncology (Bristol, England)|July 11, 2025
Thieno[2,3-<i>b</i>]pyridine compounds potently inhibit prostate cancer growth and motilityM A Alkheilewi, D A Leach, A Mohr, et al.
The Journal of Endocrinology|January 9, 2023
Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancerJ N Zamarbide Losada, E Sulpice, S Combe, et al.
Oncogene|February 6, 2026
Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS/TLS alters androgen signalling in prostate cancerG N Brooke, D A Leach, R L Culley, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Oncogene|December 20, 2011
Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgensD A Dart, G N Brooke, A Sita-Lumsden, et al.
Archives of Disease in Childhood|June 1, 1997
Phenotypic diversity in siblings with partial androgen insensitivity syndromeB A Evans, I A Hughes, C L Bevan, et al.
Human Molecular Genetics|February 1, 1996
Functional analysis of six androgen receptor mutations identified in patients with partial androgen insensitivity syndromeC L Bevan, B B Brown, H R Davies, et al.
Biochemical Society Transactions|November 1, 2006
Mechanisms of androgen receptor repression in prostate cancerS M Powell, G N Brooke, H C Whitaker, et al.
Nature Communications|July 2, 2021
The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cellsD A Leach, A Mohr, E S Giotis, et al.
Oncogene|September 12, 2006
Prohibitin, a protein downregulated by androgens, represses androgen receptor activityS C Gamble, D Chotai, M Odontiadis, et al.
International Journal of Obesity (2005)|July 18, 2020
High fat diet causes distinct aberrations in the testicular proteomeS Jarvis, L A Gethings, L Samanta, et al.
Endocrine Oncology (Bristol, England)|July 11, 2025
Thieno[2,3-<i>b</i>]pyridine compounds potently inhibit prostate cancer growth and motilityM A Alkheilewi, D A Leach, A Mohr, et al.
The Journal of Endocrinology|January 9, 2023
Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancerJ N Zamarbide Losada, E Sulpice, S Combe, et al.
Oncogene|February 6, 2026
Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS/TLS alters androgen signalling in prostate cancerG N Brooke, D A Leach, R L Culley, et al.
Pageof 3